BURLINGTON, Mass.--(BUSINESS WIRE)--Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery disease, announced today that its TVC Imaging System™ for the true vessel characterization of coronary artery disease will be highlighted in 13 presentations during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2013). TCT 2013, the world's largest educational meeting specializing in interventional cardiovascular medicine, will be held October 27-November 1, 2013 at The Moscone Center in San Francisco.
The TVC Imaging System is a first-in-class intravascular imaging system that enables clinicians to assess both the structure and composition of obstructive plaque in the coronary arteries and to guide interventional treatments for better procedural outcomes. It integrates near-infrared spectroscopy (NIRS) lipid core plaque (LCP) detection technology and enhanced intravascular ultrasound (IVUS) imaging to visualize the presence of plaques, quantify the degree of vessel stenosis (narrowing) and identify lipid core plaques prone to rupturing and causing dangerous blood clots.
“We’re pleased to announce that our TVC Imaging System will be the focus of several presentations led by the world’s premier thought-leaders in interventional cardiology at this year’s TCT meeting,” said Don Southard, president and chief executive officer of Infraredx. “As the pioneer in true vessel characterization, Infraredx provides clinicians with a comprehensive solution to enhance diagnostic accuracy, improve procedural outcomes and potentially define treatment strategies.”
The schedule for presentations featuring the TVC Imaging System is as follows:
Monday, Oct. 28th
4:23 pm
Moscone
West, 2nd Floor, Room 2007
How and When to Use IVUS, OCT, and
NIRS for Procedural Guidance
Gary Mintz, M.D.
4:40 pm
Unraveling the ACS Culprit: Insights from NIRS-IVUS
David
Erlinge, M.D., Ph.D
Moscone West, 2nd Floor, Room 2007
Tuesday, Oct. 29th
7:00 am
Moscone
North, Rm 125
Integrating Physiology and Imaging into the Cath
Lab: What Technology Should I use and How and When Should I Use it?
William
Fearon, M.D., Spencer Kubo, M.D., Emmanouil S. Brilakis, M.D., Ph.D.,
John McB.Hodgson, M.D., Bon-Kwon Koo, M.D., Ph.D., Soo-Jin Kang, M.D.
11:45 am
Moscone South, Esplanade Level, Esplanade Ballroom
Plenary
Session V. Live Cases II: New York-Presbyterian Hospital/Columbia
University Medical Center, New York, NY (Giora Weisz, M.D.)
Wednesday, Oct. 30th
2:00 pm -
6:10 pm
Vulnerable Plaque Detection and Treatment
Moscone
South, Lower Level, Room 104
3:52 pm
Vulnerable Plaque Diagnosis by NIRS-IVUS (with case
vigniettes): current Data and Prospect II David Erlinge, M.D., Ph.D.
Moscone
South, Lower Level, Room 104
Thursday, Oct. 31st
8:00 am-12:
00 pm
Next Generation Intravascular Imaging and Physiology:
RF-IVUS, OCT, NIRS, iFR, CT-FFR
Moscone South, Lower Level,
Room 104
9:05 am
Moscone South, Lower Level, Room 104
Can Detection
of Stable Coronary Plaque Composition by OCT, RF-IVUS, or
NIRSpectroscopy Replace or Supplement Physiologic Lesion Assessment?
Akiko
Maehara, M.D.
9:15 am
Moscone South, Lower Level, Room 104
Identifying
and Managing Embolic-Prone Lesions: RF-IVUS, OCT, and NIRS
Emmanouil
S. Brilakis, M.D., Ph.D.
9:25 am
Moscone South, Lower Level, Room 104
RF-IVUS, OCT,
and NIRS Findings in Patients Presenting With STEMI
David
Erlinge, M.D., Ph.D.
9:55 am
Moscone South, Lower Level, Room 104
Neoatherosclerosis:
OCT and NIRS Findings and Their Clinical Implications
Ziad A.
Ali, M.D., DPhil
10:30 am
Moscone South, Lower Level, Room 104
Geographic
Miss: VH-IVUS, OCT, and NIRSFindings and Their Clinical Importance
Marco
A. Costa, M.D., Ph.D.
11:30 am
Moscone South, Lower Level, Room 104
Case #5: NIRS
Case
Giora Weisz, M.D.
About The TVC Imaging System™
The TVC Imaging System™ is a first-in-class intravascular imaging system that holds the potential to revolutionize the management of coronary artery disease by providing information that is critical for evaluating vessel structure and composition, also known as true vessel characterization. The TVC Imaging System helps interventional cardiologists identify which patients are prone to complications during stenting. The device enables cardiologists to predict peri-procedural heart attacks by assessing not only the degree of stenosis, but also the presence and extent of lipid-rich plaques (LRP).
The device is the only multimodality imaging system to combine both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS). Through IVUS technology, the TVC Imaging System provides clear and relevant information about vessel structure, in real time. The TVC Imaging System is the only device available in both the U.S. and Europe for the detection of LCPs. NIRS measurements have been made in over 5,000 patients in over 100 hospitals worldwide.
About Infraredx, Inc.
Infraredx, Inc. is a privately-funded medical device company dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease. The company is committed to improving the safety and efficacy of coronary stenting and ultimately serving as part of a strategy to prevent initial coronary events.
Through its TVC Imaging System™, Infraredx is changing the way coronary artery disease is diagnosed and treated. The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback. Founded in 1998, Infraredx is headquartered in Burlington, Mass. For more information, visit www.infraredx.com.
